The plant will make three types of insulin, which Civica has pledged to sell for $30 a vial and $55 for a box of five pens. In 2023, Civica struck a deal to produce insulin for the state of California ...

Novo Nordisk’s semaglutide diabetes and weight loss drugs, Ozempic and Wegovy, are no longer officially in shortage in the US ...

Teladoc Health has entered into a pharmacy integration agreement with Eli Lilly's LillyDirect pharmacy partner, Gifthealth, ...

Tandem Diabetes Care, Inc.’s TNDM fourth-quarter 2024 performance was driven by its impressive range of new products. The company’s impressive strategic initiatives provide a favorable opportunity for ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

The global antidiabetics market is on a strong growth trajectory, with sales projected to soar from USD 106.3 billion in 2024 to USD 298.2 billion by 2034. This substantial increase reflects a robust ...

The "Insulin Pens Market Size by Segments, Share, Regulatory, Reimbursement and Forecast to 2036" report has been added to ResearchAndMarkets.com's offering.The report is built to visualize ...

"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...

South Africa's Competition Commission investigates Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market.

California’s low-cost insulin plan is more than a year behind schedule with no clear timeline. Advocates say the delay is ...

South African billionaire Stephen Saad says Aspen Pharmacare is ready to leverage the ‘largest opportunity in the global ...